SNX10 and central nervous system cancer: Taken together, these results show that SNX10 is required for glioblastoma growth in vivo and higher SNX10 expression portends worse prognosis in both glioma and glioblastoma patients, suggesting SNX10 as a potential therapeutic target with clinical utility for glioblastoma patients.